Australia makes genetic testing for women with family history of breast or ovarian cancer freely available, the Sydney Morning Herald reports.
Women with BRCA1 or BRCA2 mutations tell the Washington Post how learning their status has affected their life choices.
New research suggests some individuals with germline BRCA1/2 mutations who develop cancer may benefit from tumor BRCA functionality testing prior to treatment.
The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.
The Korean molecular diagnostics startup is planning to launch the new offering in Europe, as well as China and other Southeast Asian countries.
Researchers shored up their age-specific breast and ovarian cancer risk estimates by following thousands of individuals with pathogenic BRCA1/2 mutations.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The team used genome- or exome-wide analysis of participants with BRCA 1/2 mutations to come to its conclusions.
The firm will use machine learning and bioinformatics, and will generate new genomic data to help improve and personalize treatment of BRCA mutation carriers.
The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.